1684452-83-2

Basic information

• Product Name: Mirabegron Impurity
• Synonyms: N-(2-Amino-4-thiazolyl)acetyl Mirabegron
• CAS NO: 1684452-83-2
• Molecular Formula: C26H28N6O3S2
• Molecular Weight: 536.66892
• Mol File: 1684452-83-2.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 886.5±65.0 °C(Predicted)
• Appearance: /
• Density: 1.427±0.06 g/cm3(Predicted)
• PKA: 13.47±0.70(Predicted)
• CAS DataBase Reference: Mirabegron Impurity(CAS DataBase Reference)
• NIST Chemistry Reference: Mirabegron Impurity(1684452-83-2)
• EPA Substance Registry System: Mirabegron Impurity(1684452-83-2)

Safety Data

• Hazardous Substances Data: 1684452-83-2(Hazardous Substances Data)

Usage

Description

Mirabegron Impurity, specifically N-(2-Amino-4-thiazolyl)acetyl Mirabegron, is an impurity associated with Mirabegron (M364900). Mirabegron is a potent bladder relaxant and reagent used for diabetes remedy. The presence of impurities in pharmaceutical compounds is crucial to monitor and control, as they can affect the safety, efficacy, and quality of the drug.

Uses

Used in Pharmaceutical Industry:
Mirabegron Impurity is used as a quality control marker for ensuring the purity and safety of Mirabegron, a potent bladder relaxant and diabetes remedy. The presence of this impurity is monitored during the manufacturing process to maintain the drug's efficacy and to comply with regulatory standards.
Used in Research and Development:
Mirabegron Impurity serves as a valuable compound for researchers in the pharmaceutical sector. It can be used to study the effects of impurities on the overall performance of Mirabegron, as well as to develop methods for impurity detection and removal. This research can contribute to the improvement of drug formulation and the development of more effective treatments for bladder-related conditions and diabetes.
Used in Regulatory Compliance:
Mirabegron Impurity plays a role in ensuring that Mirabegron meets the required standards for quality, safety, and efficacy as set by regulatory authorities. By monitoring and controlling the levels of this impurity, pharmaceutical companies can demonstrate compliance with these standards and maintain the trust of healthcare professionals and patients.